mGluR2 mGluR5 Antagonists for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS disorders, particularly those involving metabotropic glutamate receptors, lack effective antagonists for conditions such as psychosis, schizophrenia, and Alzheimer's disease, with existing compounds having limitations in therapeutic efficacy and specificity.
Innovation Solution
Development of novel compounds of formula (I), which are metabotropic glutamate receptor antagonists, specifically targeting mGluR2 and mGluR5 receptors, offering improved therapeutic properties and specificity for treating CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing mGluR antagonists are used, then some therapeutic effect is achieved, but specificity and therapeutic efficacy are insufficient
Solution Approach 1:
The patent applies local quality by creating receptor-specific antagonists with distinct molecular structures tailored to bind selectively to specific mGluR subtypes (mGluR2 and mGluR5). The compounds feature specific substituent patterns and core structures that confer preferential affinity for target receptors over other mGluR subtypes, thereby improving both specificity and therapeutic efficacy simultaneously.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations to optimize receptor binding affinity and selectivity. By adjusting chemical parameters across a series of compounds, the invention achieves high specificity for mGluR2 and mGluR5 while maintaining potent antagonistic activity.
2Adaptability or versatility
If broad-spectrum mGluR antagonists are developed, then multiple CNS disorders can be treated, but side effects increase due to lack of specificity
Solution Approach 1:
The patent applies segmentation by dividing the mGluR receptor family into specific target groups (mGluR2 and mGluR5) and developing separate antagonist compounds for each subgroup. This segmented approach allows targeted treatment of specific disorder subtypes while avoiding the non-specific effects of broad-spectrum antagonists, thus reducing side effects while maintaining therapeutic scope.
Solution Approach 2:
The patent uses local quality to create selectively active compounds with molecular features that confer preferential binding to specific mGluR subtypes. This localized specificity ensures that each compound primarily affects its intended target receptor, minimizing off-target effects and reducing side effects while maintaining adaptability to different CNS disorders.
Data Source
AI summary
The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them: wherein A, B, X, Y, R1, R2, R3 and R4 are as defined in the description and claims.